The Atorvastatin Goal Achievement Across Risk Levels: (ATGOAL) study in Thailand.
Artículo
en Inglés
| IMSEAR
| ID: sea-39430
ABSTRACT
OBJECTIVE:
To evaluate the efficacy and safety of atorvastatin at the starting doses of 10, 20, 40 mg and evaluate the effectiveness of 1 step titrate up regimen. MATERIAL ANDMETHOD:
Two hundred and forty two subjects with dyslipidemia were enrolled and assigned the appropriate dose in relation to their individual cardiovascular risk status and baseline LDL-C levels. If the NCEP targets were not achieved, the doses were titrated up at week 4 and the primary efficacy was evaluated at week 8.RESULTS:
A majority of subjects (88.8%) achieved their LDL-C goals at week 8. Almost all of the subject's LDL-C levels reached their goals by week 2 and 4 (81.6% and 87.1%, respectively). Only 10.7% (n = 25) required the sole titration. Each dose provided significant decreases in LDL-C (average -46.4%). Only 36 subjects experienced treatment related adverse events, the majority of these were in the high-risk group (n = 22) with only one subject registering a serious adverse event.CONCLUSION:
Atorvastatin is effective and safe for Thai patients with dyslipidemia. The appropriate starting dose has contributed in the achievement of cholesterol reduction.
Texto completo:
Disponible
Índice:
IMSEAR (Asia Sudoriental)
Asunto principal:
Pirroles
/
Anciano de 80 o más Años
/
Anciano
/
Femenino
/
Humanos
/
Masculino
/
Adolescente
/
Resultado del Tratamiento
/
Medición de Riesgo
/
Inhibidores de Hidroximetilglutaril-CoA Reductasas
Tipo de estudio:
Estudio de etiología
/
Factores de riesgo
Límite:
Aged80
Idioma:
Inglés
Año:
2007
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS